automated-news
Azalea Therapeutics Highlights Nature Publication Demonstrating In Vivo Site-Specific TRAC-CAR T Cell Engineering
Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platformPeer-reviewed publication demonstrates stable, cell-specific transgene expression through in vivo site-specific integration of large DNA payloadsFindings show integration of a promoterless CAR at the TRAC locus enables physiologic CAR expression and durable anti-tumor
